Source: Pharmacy Times articles
Patients with relapsed, refractory disease achieved deep, durable responses with equecabtagene autoleucel.
Read More
Recent Content
- Equecabtagene Autoleucel Shows Efficacy, Safety in Treatment of Patients With Heavily Pretreated Multiple Myeloma
- Anitocabtagene autoleucel exhibits durable efficacy in high-risk advanced multiple myeloma
- Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
- Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
- ASH 2024: Cilta-Cel Achieves Sustained MRD Negativity in Patients With Multiple Myeloma
- Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies
- Advancements in Multiple Myeloma Therapies and Operational Insights in Oncology Clinical Trials
- Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
- Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
- Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3